Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Cancer Research Communications|2023Cited by 19
Supplementary Materials and Methods from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0
Supplementary Materials and Methods from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0
Supplementary Figure 4 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0
Data from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0